Incyte INCY announced new 24-week interim data from the STOP-HS program on pipeline candidate, povorcitinib (INCB54707), in ...

Incyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa ...

Sanofi’s brivekimig met the primary endpoint in a Phase IIa trial in patients naïve to biologics with moderate-to-severe ...

Incyte (INCY) announced new 24-week interim data evaluating the safety and efficacy of povorcitinib, an oral small-molecule highly-selective JAK1 ...

EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study In phase 2a study, brivekimig led to clinically meaningful improvements in primary and key secondary ...

Some of Sanofi’s most high-profile readouts this year can’t have made for easy reading at the French pharma’s Paris ...

New data from the HS-OBTAIN Phase IIa study (clinical study identifier: show that treatment with brivekimig led to clinically-meaningful improvements in the primary endpoint of hidradenitis ...